132 related articles for article (PubMed ID: 38752352)
21. Sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: A Phase IIb, randomised, double-blind, placebo-controlled study - Rationale and study design.
Behr J; Nathan SD; Harari S; Wuyts W; Kirchgaessler KU; Bengus M; Gilberg F; Wells AU
Respir Med; 2018 May; 138():13-20. PubMed ID: 29724385
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of oral sildenafil in children with Down syndrome and pulmonary hypertension.
Beghetti M; Rudzinski A; Zhang M
BMC Cardiovasc Disord; 2017 Jul; 17(1):177. PubMed ID: 28676038
[TBL] [Abstract][Full Text] [Related]
23. A modeling and simulation-based assessment of the impact of confounding factors on the readout of a sildenafil survival trial in pulmonary arterial hypertension.
Chanu P; Gao X; Bruno R; Claret L; Harnisch L
J Pharmacokinet Pharmacodyn; 2019 Oct; 46(5):499-509. PubMed ID: 31538282
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: a double-blind, randomised, placebo-controlled, phase 2b trial.
Behr J; Nathan SD; Wuyts WA; Mogulkoc Bishop N; Bouros DE; Antoniou K; Guiot J; Kramer MR; Kirchgaessler KU; Bengus M; Gilberg F; Perjesi A; Harari S; Wells AU
Lancet Respir Med; 2021 Jan; 9(1):85-95. PubMed ID: 32822614
[TBL] [Abstract][Full Text] [Related]
25. On-Demand Sildenafil as a Treatment for Raynaud Phenomenon: A Series of n-of-1 Trials.
Roustit M; Giai J; Gaget O; Khouri C; Mouhib M; Lotito A; Blaise S; Seinturier C; Subtil F; Paris A; Cracowski C; Imbert B; Carpentier P; Vohra S; Cracowski JL
Ann Intern Med; 2018 Nov; 169(10):694-703. PubMed ID: 30383134
[TBL] [Abstract][Full Text] [Related]
26. Sildenafil improves renal function in patients with pulmonary arterial hypertension.
Webb DJ; Vachiery JL; Hwang LJ; Maurey JO
Br J Clin Pharmacol; 2015 Aug; 80(2):235-41. PubMed ID: 25727860
[TBL] [Abstract][Full Text] [Related]
27. Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a multicenter, double-blind, randomized clinical trial.
Bermejo J; Yotti R; García-Orta R; Sánchez-Fernández PL; Castaño M; Segovia-Cubero J; Escribano-Subías P; San Román JA; Borrás X; Alonso-Gómez A; Botas J; Crespo-Leiro MG; Velasco S; Bayés-Genís A; López A; Muñoz-Aguilera R; de Teresa E; González-Juanatey JR; Evangelista A; Mombiela T; González-Mansilla A; Elízaga J; Martín-Moreiras J; González-Santos JM; Moreno-Escobar E; Fernández-Avilés F;
Eur Heart J; 2018 Apr; 39(15):1255-1264. PubMed ID: 29281101
[TBL] [Abstract][Full Text] [Related]
28. Tadalafil for the treatment of pulmonary arterial hypertension: a double-blind 52-week uncontrolled extension study.
Oudiz RJ; Brundage BH; Galiè N; Ghofrani HA; Simonneau G; Botros FT; Chan M; Beardsworth A; Barst RJ;
J Am Coll Cardiol; 2012 Aug; 60(8):768-74. PubMed ID: 22818063
[TBL] [Abstract][Full Text] [Related]
29. Effects of sildenafil on maximum walking time in patients with arterial claudication: The ARTERIOFIL study.
Omarjee L; Le Pabic E; Custaud MA; Fontaine C; Locher C; Renault A; Jaquinandi V; Azzola V; Barbeau-Terrier C; Laporte I; Ripoche M; Onillon Y; Chretien JM; Daniel V; Chao de la Barca JM; Homedan C; Reynier P; Abraham P; Mahé G
Vascul Pharmacol; 2019; 118-119():106563. PubMed ID: 31152977
[TBL] [Abstract][Full Text] [Related]
30. Pulmonary vasodilator therapies in pulmonary arterial hypertension associated with CHD: a systematic review and network meta-analysis.
Yasuhara J; Watanabe K; Watanabe A; Shirasu T; Matsuzaki Y; Watanabe H; Takagi H; Sumitomo N; Kuno T
Cardiol Young; 2023 Nov; 33(11):2297-2311. PubMed ID: 36721907
[TBL] [Abstract][Full Text] [Related]
31. Conversion from sildenafil to tadalafil: results from the sildenafil to tadalafil in pulmonary arterial hypertension (SITAR) study.
Frantz RP; Durst L; Burger CD; Oudiz RJ; Bourge RC; Franco V; Waxman AB; McDevitt S; Walker S
J Cardiovasc Pharmacol Ther; 2014 Nov; 19(6):550-7. PubMed ID: 24742768
[TBL] [Abstract][Full Text] [Related]
32. Sildenafil in severe pulmonary hypertension associated with chronic obstructive pulmonary disease: A randomized controlled multicenter clinical trial.
Vitulo P; Stanziola A; Confalonieri M; Libertucci D; Oggionni T; Rottoli P; Paciocco G; Tuzzolino F; Martino L; Beretta M; Callari A; Amaducci A; Badagliacca R; Poscia R; Meloni F; Refini RM; Geri P; Baldi S; Ghio S; D'Alto M; Argiento P; Sofia M; Guardamagna M; Pezzuto B; Vizza CD
J Heart Lung Transplant; 2017 Feb; 36(2):166-174. PubMed ID: 27329400
[TBL] [Abstract][Full Text] [Related]
33. Sildenafil for the treatment of pulmonary hypertension in children.
Beghetti M; Wacker Bou Puigdefabregas J; Merali S
Expert Rev Cardiovasc Ther; 2014 Oct; 12(10):1157-84. PubMed ID: 25223406
[TBL] [Abstract][Full Text] [Related]
34. A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertension.
Barst RJ; Ivy DD; Gaitan G; Szatmari A; Rudzinski A; Garcia AE; Sastry BK; Pulido T; Layton GR; Serdarevic-Pehar M; Wessel DL
Circulation; 2012 Jan; 125(2):324-34. PubMed ID: 22128226
[TBL] [Abstract][Full Text] [Related]
35. Sildenafil for pulmonary hypertension in neonates.
Kelly LE; Ohlsson A; Shah PS
Cochrane Database Syst Rev; 2017 Aug; 8(8):CD005494. PubMed ID: 28777888
[TBL] [Abstract][Full Text] [Related]
36. Rationale and study design of RESPITE: An open-label, phase 3b study of riociguat in patients with pulmonary arterial hypertension who demonstrate an insufficient response to treatment with phosphodiesterase-5 inhibitors.
Hoeper MM; Klinger JR; Benza RL; Simonneau G; Langleben D; Naeije R; Corris PA
Respir Med; 2017 Jan; 122 Suppl 1():S18-S22. PubMed ID: 27887774
[TBL] [Abstract][Full Text] [Related]
37. A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension.
Singh TP; Rohit M; Grover A; Malhotra S; Vijayvergiya R
Am Heart J; 2006 Apr; 151(4):851.e1-5. PubMed ID: 16569546
[TBL] [Abstract][Full Text] [Related]
38. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension.
Michelakis ED; Tymchak W; Noga M; Webster L; Wu XC; Lien D; Wang SH; Modry D; Archer SL
Circulation; 2003 Oct; 108(17):2066-9. PubMed ID: 14568893
[TBL] [Abstract][Full Text] [Related]
39. [Two-year follow-up of pulmonary arterial hypertension patients treated with sildenafil].
Franchi SM; Barreto AC; Cícero C; Castro CR; Ribeiro ZV; Lopes AA
Arq Bras Cardiol; 2010 May; 94(5):671-7. PubMed ID: 20428715
[TBL] [Abstract][Full Text] [Related]
40. Treatment of pulmonary arterial hypertension using extemporaneous formulation of sildenafil in Mexican children.
Juárez Olguín H; Camacho Reyes L; Roldan Arce A; Calderón Guzmán D
Pediatr Cardiol; 2015 Jun; 36(5):1019-23. PubMed ID: 25612785
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
